| 发明名称 |
XYLANASE VARIANTS AND POLYNUCLEOTIDES ENCODING SAME |
| 摘要 |
The present invention relates to xylanase variants, comprising an alteration at least at one position corresponding to position 87 of the polypeptide of SEQ ID NO: 3, wherein the variant has xylanase activity and has increased xylanase inhibitor tolerance compared to the xylanase of SEQ ID NO: 3; and i) wherein the variant has at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99%, but less than 100% sequence identity to the polypeptide of SEQ ID NO: 3; or ii) wherein the number of alterations is 1-20, e.g., 1-10 such as 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 alterations. The present invention also relates to polynucleotides encoding the variants; nucleic acid constructs, vectors, and host cells comprising the polynucleotides; and methods of using the variants. |
| 申请公布号 |
US2017096687(A1) |
申请公布日期 |
2017.04.06 |
| 申请号 |
US201515315539 |
申请日期 |
2015.06.25 |
| 申请人 |
NOVOZYMES A/S |
发明人 |
Scott Brian R.;Wogulis Mark David;Pedersen Sven;Lavigne James |
| 分类号 |
C12P7/10;C12N15/52;C12N15/82;C12N9/24 |
主分类号 |
C12P7/10 |
| 代理机构 |
|
代理人 |
|
| 主权项 |
1. A xylanase variant, comprising an alteration at least at one position corresponding to position 87 of the polypeptide of SEQ ID NO: 3, wherein the variant has xylanase activity and has increased xylanase inhibitor tolerance compared to the xylanase of SEQ ID NO: 3; and
i) wherein the variant has at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99%, but less than 100% sequence identity to the polypeptide of SEQ ID NO: 3; or ii) wherein the number of alterations is 1-20, e.g., 1-10 such as 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 alterations. |
| 地址 |
Bagsvaerd DK |
